Effects of Torcetrapib in Patients at High Risk for Coronary Events
Top Cited Papers
- 22 November 2007
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 357 (21), 2109-2122
- https://doi.org/10.1056/nejmoa0706628
Abstract
Inhibition of cholesteryl ester transfer protein (CETP) has been shown to have a substantial effect on plasma lipoprotein levels. We investigated whether torcetrapib, a potent CETP inhibitor, might reduce major cardiovascular events. The trial was terminated prematurely because of an increased risk of death and cardiac events in patients receiving torcetrapib. We conducted a randomized, double-blind study involving 15,067 patients at high cardiovascular risk. The patients received either torcetrapib plus atorvastatin or atorvastatin alone. The primary outcome was the time to the first major cardiovascular event, which was defined as death from coronary heart disease, nonfatal myocardial infarction, stroke, or hospitalization for unstable angina. At 12 months in patients who received torcetrapib, there was an increase of 72.1% in high-density lipoprotein cholesterol and a decrease of 24.9% in low-density lipoprotein cholesterol, as compared with baseline (P<0.001 for both comparisons), in addition to an increase of 5.4 mm Hg in systolic blood pressure, a decrease in serum potassium, and increases in serum sodium, bicarbonate, and aldosterone (P<0.001 for all comparisons). There was also an increased risk of cardiovascular events (hazard ratio, 1.25; 95% confidence interval [CI], 1.09 to 1.44; P=0.001) and death from any cause (hazard ratio, 1.58; 95% CI, 1.14 to 2.19; P=0.006). Post hoc analyses showed an increased risk of death in patients treated with torcetrapib whose reduction in potassium or increase in bicarbonate was greater than the median change. Torcetrapib therapy resulted in an increased risk of mortality and morbidity of unknown mechanism. Although there was evidence of an off-target effect of torcetrapib, we cannot rule out adverse effects related to CETP inhibition. (ClinicalTrials.gov number, NCT00134264.)Keywords
This publication has 15 references indexed in Scilit:
- HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular EventsThe New England Journal of Medicine, 2007
- Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbitsJournal of Lipid Research, 2007
- Efficacy and Safety of Torcetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor, in Individuals With Below-Average High-Density LipoproteinCholesterolLevelsonaBackgroundofAtorvastatinJournal of the American College of Cardiology, 2006
- Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart diseasePharmacology & Therapeutics, 2006
- Targeting Cholesteryl Ester Transfer Protein for the Prevention and Management of Cardiovascular DiseaseJournal of the American College of Cardiology, 2006
- HDL as a target in the treatment of atherosclerotic cardiovascular diseaseNature Reviews Drug Discovery, 2005
- Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL CholesterolThe New England Journal of Medicine, 2004
- Cholesteryl Ester Transfer ProteinArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Pros and cons of inhibiting cholesteryl ester transfer proteinCurrent Opinion in Lipidology, 2000
- High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.Circulation, 1989